COMMON STOCK | 4. COMMON STOCK At March 31, 2018, the Company's authorized capital stock was 150,000,000 shares of common stock, par value $0.001 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share. As of that date, the Company had outstanding 43,670,765 shares of common stock, and no shares of preferred stock. During the three months ended March 31, 2018 and 2017, the Company did not issue any shares. Stock and Warrant Grants: In January 2018, the Company granted 500,000 shares of restricted common stock to an employee of the Company with a fair market value of $335,000 or $0.67 per share. The 500,000 shares have an annual vesting period of five years with the first vesting period occurring on December 31, 2018. The amount vested and expensed of this grant for the three months ended March 31, 2018 totaled $16,749. As of March 31, 2018, none of the shares have been issued. In January 2018, the Company granted 500,000 shares of restricted common stock to an employee of the Company with a fair market value of $349,900 or $0.6998 per share. The 500,000 shares have an annual vesting period of five years with the first vesting period occurring on December 31, 2018. The amount vested and expensed of this grant for the three months ended March 31, 2018 totaled $17,494. As of March 31, 2018, none of the shares have been issued. In January 2018, the Company granted 490,000 shares of restricted common stock to an employee of the Company with a fair market value of $362,600 or $0.74 per share. 90,000 shares will vest on December 31, 2018 and the remaining 400,000 shares have an annual vesting period of four years with the first vesting period occurring on December 31, 2019. The amount vested and expensed of this grant for the three months ended March 31, 2018 totaled $16,650. As of March 31, 2018, none of the shares have been issued. In January 2018, the Company granted 150,000 shares of restricted common stock to an employee of the Company with a fair market value of $110,850. The 150,000 shares have an annual vesting period of five years with the first vesting period occurring on December 31, 2018. The amount vested and expensed of this grant for the three months ended March 31, 2018 totaled $5,543. As of March 31, 2018, none of the shares have been issued. In January 2018, the Company granted 100,000 shares of restricted common stock to an employee of the Company with a fair market value of $71,000, or $0.71 per share. The 100,000 shares have an annual vesting period of one year to be fully vested on December 31, 2018. The amount vested and expensed of this grant for the three months ended March 31, 2018 totaled $17,750. As of March 31, 2018, none of the shares have been issued. In July 2017 the Company granted 200,000 shares of restricted common stock to an employee of the Company with a total fair value of $84,400 or $0.422 per share which these shares have been issued. Concurrently, the Company also granted the employee four equal tranches of 200,000 restricted common shares, each valued at $84,400 which will vest in equal amounts over a four year period on the last day of each quarter, commencing December 31, 2017. None of the shares subject to vesting restrictions have been issued. In November 2016, the Company granted a total of 5,000,000 shares to certain officers and directors of the Company with a total value of $787,950 or $0.15759 per share (including a 15% discount to fair market value due to these shares being restricted and lacking market liquidity). The 5,000,000 shares have a quarterly vesting period of five years with the first vesting period occurring on December 31, 2016. The amount vested and expensed for the three months ended March 31, 2018 and 2017 was $39,397 and $39,397 respectively As of March 31, 2018, none of the shares have been issued. In November 2016, the Company granted 210,000 shares to a consultant. The shares were valued at $33,094 or $0.15759 per share (including a 15% discount to fair market value due to these shares being restricted and lacking market liquidity). The 210,000 shares have a quarterly vesting period of three years with the first vesting period occurring on December 31, 2016. The amount vested and expensed for the three months ended March 31, 2018 and 2017 was $2,758 and $2,758 respectively. As of March 31, 2018, none of the shares have been issued In March 2015, the Company granted 200,000 shares of common stock along with 200,000 warrants to a consultant. The shares were valued at $30,600 or $0.16 per share (including a 15% discount to fair market value due to these shares being restricted and lacking market liquidity). The warrants were valued at $34,611, using the Black-Scholes options pricing model under the following assumptions: stock price at issuance of $0.18 per share; exercise price of $0.50, 3.5 year life; discount rate of 2.00%; and volatility rate of 245%. The 200,000 shares and 200,000 warrants granted have a vesting period of six months of which one month were fully vested as of March 31, 2016. As of March 31, 2018, the 200,000 shares have been issued and the warrants for 200,000 shares were granted. |